<DOC>
	<DOC>NCT02420821</DOC>
	<brief_summary>This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.</brief_summary>
	<brief_title>A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Definitive diagnosis of unresectable locally advanced or metastatic RCC with clearcell histology and/or a component of sarcomatoid carcinoma, with no prior treatment in the metastatic setting Evaluable Memorial Sloan Kettering Cancer Center risk score Measurable disease, as defined by RECIST v1.1 Karnofsky performance status greater than or equal to 70% Adequate hematologic and endorgan function prior to randomization DiseaseSpecific Exclusions: Radiotherapy for RCC within 14 days prior to treatment Active central nervous system disease Uncontrolled pleural effusion, pericardial effusion, or ascites Uncontrolled hypercalcemia Any other malignancies within 5 years except for lowrisk prostate cancer or those with negligible risk of metastasis or death General Medical Exclusions: Life expectancy less than 12 weeks Participation in another experimental drug study within 4 weeks prior to treatment Pregnant or lactating women Known hypersensitivity to any component of atezolizumab or other study medication History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes mellitus History of idiopathic pulmonary fibrosis, organizing pneumonia, druginduced pneumonitis, or idiopathic pneumonitis Positive human immunodeficiency virus test Active or chronic hepatitis B or C Severe infections within 4 weeks prior to treatment Exposure to oral or IV antibiotics within 2 weeks prior to treatment Live attenuated vaccines within 4 weeks prior to treatment, 28 days prior to randomization, during treatment, or within 5 months following last dose of atezolizumab Significant cardiovascular disease Prior allogeneic stem cell or solid organ transplantation Exclusion Criteria Related to Medications: Prior treatment with cluster of differentiation 137 agonists, anticytotoxic Tlymphocyte associated protein4, antiprogrammed death (PD)1, or antiPDL1 therapeutic antibody or pathwaytargeting agents Treatment with immunostimulatory agents for nonmalignant conditions within 6 weeks or immunosuppressive agents within 2 weeks prior to treatment Bevacizumab and SunitinibSpecific Exclusions: History of hypertensive crisis or hypertensive encephalopathy Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>